PLYX Polaryx Therapeutics, Inc.
Distress ·
The company says its cash lasts through the first quarter of 2027 and it will need more capital after that. SOTERIA is due to start in the second half of 2026.
Prices ran from $3.70 to $4.10 a share depending on commitment size. MStone Partners, the largest holder, bought $360,000 of stock.
Polaryx began trading on Nasdaq on February 2, 2026 without an underwriter, and the company received no money from the listing.
Polaryx's 1-for-4 reverse split took effect on January 12, 2026, ahead of a Nasdaq direct listing that raised no money for the company.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $6.3 million | $2.8 million |
| Net income (loss) | -$9.0 million | -$30.4 million |
| Cash from operations | -$3.9 million | -$2.6 million |
| Cash and equivalents | $5.1 million | $4.6 million |
Our latest story on this, dated Jan 12, 2026: "Polaryx completes one-for-four reverse stock split ahead of Nasdaq listing". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 13, 2026: "Polaryx reports $11.5 million cash, funding into early 2027 and going-concern doubt". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Feb 2, 2026: "Polaryx begins Nasdaq trading through a direct listing". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 28, 2026: "Polaryx closes $10 million private placement with about 35 investors". The story links the filing or release it is based on. Read the story.
Polaryx Therapeutics, Inc. trades under the ticker PLYX on NASDAQ.
Polaryx Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Polaryx Therapeutics, Inc. is 2075320. Its filings are on SEC EDGAR.
49,845,993 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-13.
Our directory records Polaryx Therapeutics, Inc. under United States.
Our directory classifies Polaryx Therapeutics, Inc. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Polaryx Therapeutics, Inc. is US73110F1003.
aibio.space lists Polaryx Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as WY.
Polaryx Therapeutics, Inc. reported a net loss of $9.0 million for the fiscal year ended Dec 31, 2025, and used $3.9 million of cash in operations, per its annual report to the SEC.
$6.3 million in the fiscal year ended Dec 31, 2025, per its annual report.
The new chief medical officer appointment became effective. Source
The quarterly report retained substantial doubt alongside an estimate that cash would fund operations through the first quarter of 2027. Source
The chief medical officer resigned; the company said its disclosed development timelines were not expected to change. Source
The private placement closed for $10 million gross. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Polaryx signed the common-stock private-placement purchase agreement. Source
The annual report disclosed substantial doubt about continuing operations. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Polaryx implemented the one-for-four common-stock consolidation. Source
The later crowdfunding update reported $45,024.70 aggregate proceeds and 68,756 securities. Source
A crowdfunding progress update reported $23,014.60 and 35,301 securities at the close of the offering; a later update reported an aggregate of $45,024.70. Source
The prospectus says the company receives no proceeds from registered-holder resales. Listing and a new issuer cash raise are distinct. Source
The annual report states that trading began on 2026-02-02 on the Nasdaq Capital Market. Source
Cash and equivalents were $11.542 million at 2026-06-30. Source balance-sheet amounts are in thousands of dollars. Source
The quarterly report projected funding through the first quarter of 2027. It is a plan-based estimate rather than an exact exhaustion date. Source
Yes. The quarterly liquidity note says the company's conditions raise substantial doubt about its ability to continue as a going concern for twelve months from the date the statements were available to be issued. Source
The company reported closing its common-share placement on 2026-05-28 for $10 million gross. Source
The company completed a one-for-four common-stock split effective on 2026-01-12. Historical share data in the cited reports are adjusted for it. Source
The annual report is signed by Grant Thornton LLP, which states service since 2024. Source
The later progress report states an aggregate $45,024.70 and 68,756 securities. The earlier progress amount is not added to that aggregate. Source
No. The fee table describes shares available for future plan issuance; it does not announce a completed subscription receipt. Source
The company says it was not party to material legal proceedings at that time. This is a dated issuer statement, not a comprehensive independent court search. Source
No. The proxy attributes overlapping voting interests in the Mstone entities to the CEO. Adding both rows would count the same interests twice. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio